Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KW 2307

Known as: KW-2307 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Vinorelbine (Navelbine, KW-2307), a semisynthetic vinca alkaloid, is a potent inhibitor of mitotic microtubule polymerization… Expand
1995
1995
A multicenter cooperative study was performed to compare KW-2307 (KW), a novel vinca alkaloid (VA) derivative, and vindesine (VDS… Expand
1994
1994
A multicenter early Phase II clinical study of KW-2307, a new vinca alkaloid derivative, in patients (pts) with lung cancer was… Expand
1994
1994
A multi-institutional early phase II study of KW-2307 (vinorelbine), a new vinca alkaloid derivative, in advanced or recurrent… Expand
1994
1994
Phase I study on a new vinca alkaloid derivative, KW-2307(vinorelbine), was conducted by multiple institutions in 40 patients… Expand
1994
1994
A phase-I clinical study with coadministration of a new vinca alkaloid derivative KW-2307 with cisplatin (CDDP) at 80 mg/m2 to… Expand
1993
1993
The in vivo combination effect of navelbine (NVB, KW-2307) plus cisplatin was compared with that of vindesine (VDS) plus… Expand
1993
1993
1. KW-2307 (vinorelbine ditartrate, CAS71486-22-1) is a new semisynthetic antitumour vinca alkaloid. Its pharmacokinetics… Expand
1992
1992
The combination effect of navelbine (NVB, KW-2307), a newly synthesized vinca alkaloid, and cisplatin (CDDP) was compared with… Expand
1992
1992
The combination effect of navelbine (NVB, KW‐2307), a newly synthesized vinca alkaloid, and cisplatin (CDDP) was compared with… Expand